Belumosudil
- Generic Name
- Belumosudil
- Brand Names
- Rezurock
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N6O2
- CAS Number
- 911417-87-3
- Unique Ingredient Identifier
- 834YJF89WO
- Background
Belumosudil is used in the treatment of chronic graft-versus-host disease (GVHD) and has been investigated for the treatment of pulmonary arterial hypertension. It is an inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK), with significantly more selectivity for ROCK2 as compared to ROCK1 (IC 100 nM vs. 3 μM, respectively). In the treat...
- Indication
Belumosudil is indicated for the treatment of chronic graft-versus-host disease (GVHD) in adult and pediatric patients 12 years of age and older following failure of at least two other lines of systemic therapy.
- Associated Conditions
- Chronic Graft-Versus-Host Disease
- Associated Therapies
- -
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
- First Posted Date
- 2020-11-24
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 197
- Registration Number
- NCT04643002
- Locations
- 🇮🇱
Investigational Site Number : 3760002, Jerusalem, Israel
🇫🇷Investigational Site Number : 2500002, Lille, France
🇫🇷Investigational Site Number : 2500001, Nantes, France
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT03530995
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
A Phase 2, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Belumosudil in Subjects With Moderate/Severe Chronic Plaque Psoriasis
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 110
- Registration Number
- NCT02852967
- Locations
- 🇺🇸
Austin Institute for Clinical Research, Pflugerville, Texas, United States
🇺🇸Psoriasis Treatment Center of Central New Jersey, East Windsor, New Jersey, United States
🇺🇸Renstar Medical Research, Ocala, Florida, United States
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 76
- Registration Number
- NCT02688647
- Locations
- 🇺🇸
Central Florida Pulmonary Group, PA, Orlando, Florida, United States
🇺🇸Piedmont Healthcare Pulmonary and Critical Care Research, Austell, Georgia, United States
🇺🇸Pulmonary Associates, PA, Phoenix, Arizona, United States
A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 8
- Registration Number
- NCT02106195
- Locations
- 🇺🇸
UC Irvine Health, Dept of Dermatology, Irvine, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.